GLP-1 & Incretin Science

What Is Pramlintide? The First Clinical Amylin Analogue

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Pramlintide is a synthetic analogue of human amylin and the first to reach clinical use. Human amylin aggregates into amyloid fibrils, making it undeliverable; pramlintide substitutes three residues with prolines borrowed from rat amylin, which does not aggregate. Its short half-life required dosing with meals.

Key facts

Class
Amylin analogue
Molecular weight
~3,949 Da
Molecular formula
C171H267N51O53S2
PubChem CID
70691388
Parent hormone
Human amylin (37 residues)
Key modification
Proline substitutions from rat amylin
Dosing
With meals (short half-life)
Successor
Cagrilintide (weekly)

The aggregation problem

Human amylin has a strong propensity to self-assemble into amyloid fibrils. This is not merely a formulation nuisance: it is the same process that deposits islet amyloid in the pancreas in type 2 diabetes. A peptide that turns into insoluble fibrils cannot be delivered reliably, so aggregation had to be solved before amylin pharmacology could be used at all.

The solution came from rodents

Rat amylin does not form amyloid, and the difference traces to a small number of residues in the aggregation-prone region. Pramlintide substitutes prolines at those positions, borrowing rat amylin's resistance. Proline disrupts the regular backbone geometry that β-sheet amyloid assembly requires, so the substitution removes the capacity to fibrillise while retaining receptor activity.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why it needed meal-time dosing

Pramlintide has a short half-life and no half-life extension technology: no fatty acid, no albumin binding. Amylin's physiological role is meal-associated, so meal-time dosing matched the biology, but it meant multiple injections a day alongside insulin. That practical burden limited uptake regardless of pharmacology.

What changed with cagrilintide

Cagrilintide is engineered for once-weekly administration, which brings amylin into the same dosing rhythm as modern GLP-1 analogues. That is what makes a fixed-dose weekly combination such as CagriSema possible. Pairing a weekly GLP-1 agonist with a meal-time amylin analogue would not be a practical product.

Why pramlintide matters historically

It established that amylin receptor agonism was achievable and tolerable in people, and that the aggregation barrier could be engineered around. Everything in the current amylin combination pipeline (cagrilintide, amycretin) rests on that being settled two decades earlier.

Frequently asked questions

Is pramlintide a GLP-1 drug?

No. It is an amylin analogue, acting at the amylin receptor complex through a satiety pathway distinct from GLP-1's.

Why does human amylin form amyloid but rat amylin does not?

A small number of residue differences in the aggregation-prone region. Pramlintide borrows rat amylin's prolines at those positions.

How does pramlintide differ from cagrilintide?

Pramlintide is short-acting and dosed with meals. Cagrilintide is engineered for weekly administration, which makes weekly combination products possible.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.